TY - JOUR
T1 - The Effect of Atorvastatin on Lipid Profile and Inflammatory Marker in patient with Diabetes Dyslipidemia
AU - Bellatasie, Rezlie
AU - Suharjono, Suharjono
AU - Samsulhadi, Wiwid
AU - Ayumuyas, Nur Palestin
N1 - Funding Information:
The authors would like to thank the Director of the Surabaya Hajj General Hospital and Head of the Internal Medicine Departement who has facilitated data collection in this study. Highest appreciation for all participants and their caretakers who fully support this study. Part of the result of this study published under the same of corresponding author42.
Publisher Copyright:
© RJPT All right reserved.
PY - 2022/9
Y1 - 2022/9
N2 - Inflammation is the underlying cause of several comorbid diseases, including macrovascular complications that cause the highest mortality in diabetes patients. One of the pro-inflammatory cytokines used to assess inflammatory conditions in diabetes and its complications is IL-6. This study intends to analyze the effect of atorvastatin administration on lipid profile and inflammatory markers after 30 days and the correlation between lipid profile and IL-6. An observational prospective cohort study was conducted from November 2017 to January 2018 and approved by the ethical committee of General Hajj Hospital, Surabaya. Nineteen patients who met the inclusion criteria and signed the informed consent enrolled in this study. The measurement of lipid profile and IL-6 level were done twice, before and after 30 days of atorvastatin therapy. After atorvastatin administration, there was a 40.55% decrease in LDL level, a 15.34% decrease in TG level, a 30.70% decrease in total cholesterol level, which was statistically significant (p<0.05), and a 6.06% increase in HDL level. There was a 5.76% decrease in the IL-6 level (p>0.05). In conclusion, atorvastatin administration can improve lipid profile in diabetes patients with dyslipidemia. There was a decrease in IL-6 but not statistically different. From statistical analysis, there is no correlation found between lipid profile and IL-6.
AB - Inflammation is the underlying cause of several comorbid diseases, including macrovascular complications that cause the highest mortality in diabetes patients. One of the pro-inflammatory cytokines used to assess inflammatory conditions in diabetes and its complications is IL-6. This study intends to analyze the effect of atorvastatin administration on lipid profile and inflammatory markers after 30 days and the correlation between lipid profile and IL-6. An observational prospective cohort study was conducted from November 2017 to January 2018 and approved by the ethical committee of General Hajj Hospital, Surabaya. Nineteen patients who met the inclusion criteria and signed the informed consent enrolled in this study. The measurement of lipid profile and IL-6 level were done twice, before and after 30 days of atorvastatin therapy. After atorvastatin administration, there was a 40.55% decrease in LDL level, a 15.34% decrease in TG level, a 30.70% decrease in total cholesterol level, which was statistically significant (p<0.05), and a 6.06% increase in HDL level. There was a 5.76% decrease in the IL-6 level (p>0.05). In conclusion, atorvastatin administration can improve lipid profile in diabetes patients with dyslipidemia. There was a decrease in IL-6 but not statistically different. From statistical analysis, there is no correlation found between lipid profile and IL-6.
KW - Atorvastatin
KW - IL-6
KW - diabetes
KW - dyslipidemia
KW - lipid profile
UR - http://www.scopus.com/inward/record.url?scp=85144697970&partnerID=8YFLogxK
U2 - 10.52711/0974-360X.2022.00689
DO - 10.52711/0974-360X.2022.00689
M3 - Article
AN - SCOPUS:85144697970
SN - 0974-3618
VL - 15
SP - 4105
EP - 4110
JO - Research Journal of Pharmacy and Technology
JF - Research Journal of Pharmacy and Technology
IS - 9
ER -
